InvestorLens

BBIO — BRIDGEBIO PHARMA INC

Public company

Sign in to save6 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying BBIO?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
67
Institutional Conviction
Mixed · 4 buying vs 2 selling last quarter
49
Macro Tailwind
Macro conditions are mixed for this sector
56
Congressional Activity
2 congressional purchases, 0 sales disclosed in the last 6 months
Why? — Evidence & Confidence ▾

Of 6 tracked investors who changed their BBIO position last quarter, 4 bought and 2 sold (67% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime). 2 congressional purchases, 0 sales disclosed in the last 6 months.

Supporting evidence
  • +4 tracked investors added or increased positions last quarter (Ken Griffin, Ray Dalio, Steve Cohen, …)
  • +6 tracked investors reported holding BBIO at their latest filing
  • +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
  • +2 congressional purchases disclosed in the last 6 months
Contradicting evidence — always shown
  • −2 tracked investors reduced or exited last quarter (2 reduced, 0 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About BRIDGEBIO PHARMA INC (BBIO)

BRIDGEBIO PHARMA INC (BBIO) appears in the most recent 13F filings of 6 tracked institutional investors. The largest disclosed position is held by Andreas Halvorsen (Viking Global Investors), valued at $1.1B. Across recent filings, tracked investors recorded 11 new positions, 18 increased, 15 reduced, and 5 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in BBIO

59
/100
Mixed Activity
Added / Increased29
Reduced15
Exited5
BearishBullish
Crowded Trade Score™

How many top investors track BBIO

40
/100
Moderate Interest
6investors

Several tracked investors have exposure.

UndiscoveredCrowded
151015+

BBIO Ownership Composition

How BRIDGEBIO PHARMA INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Other
58% of tracked value
Institutions
6
tracked investors
Total Reported
$1.3B
combined 13F value
Types3
  • Other58.4%
  • Multi-Strategy / Quant38.3%
  • Macro3.3%
Other(1)
58.4%
Multi-Strategy / Quant(3)
38.3%
Macro(2)
3.3%

Tracked investors currently reporting BBIO

2 tracked investors have since exited this position — listed separately below.

  • Andreas HalvorsenJun 30, 2026
    Viking Global Investors
    Shares
    9.9M
    Value
    $741M
    % Portfolio
    2.11%
  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    4.3M
    Value
    $322.3M
    % Portfolio
    0.04%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    1.5M
    Value
    $114.2M
    % Portfolio
    0.13%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    669.8K
    Value
    $49.9M
    % Portfolio
    0.02%
  • Ray DalioJun 30, 2026
    Bridgewater Associates
    Shares
    448.1K
    Value
    $33.4M
    % Portfolio
    0.14%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    109.7K
    Value
    $8.2M
    % Portfolio
    0.01%

Previously held BBIO

These investors reported BBIO in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Howard MarksOaktree Capital Management10.8M$10.6MSep 30, 2025
Stanley DruckenmillerDuquesne Family Office438.1K$15.1MMar 31, 2025

Recent activity

Frequently asked questions

How many institutional investors hold BBIO?
6 tracked institutional investors disclosed a position in BBIO (BRIDGEBIO PHARMA INC) in their most recent 13F filing.
Who is the largest institutional holder of BBIO?
Andreas Halvorsen, Viking Global Investors, holds the largest disclosed position in BBIO, valued at $1.1B.
Did institutional ownership of BBIO increase or decrease?
Across recent 13F filings, tracked investors recorded 11 new positions, 18 increased, 15 reduced, and 5 fully exited BBIO.
Where does this BBIO ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
BBIO (BRIDGEBIO PHARMA INC) — Institutional Holders & 13F — InvestorLens